Cargando...
Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
Recent phase I studies have reported single-agent activities of poly (ADP-ribose) polymerase (PARP) inhibitor in sporadic and in BRCA-mutant prostate cancers. Two of the most common genetic alterations in prostate cancer, ETS gene rearrangement and loss of PTEN, have been linked to increased sensiti...
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4023365/ https://ncbi.nlm.nih.gov/pubmed/24589464 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1008-682X.123684 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|